Holding Onto Billions, Astellas (ALPMY) CEO Hunts for Next Blockbuster
11/30/2016 7:53:16 AM
A $110 million bet on a prostate cancer medicine gave Astellas Pharma Inc. a blockbuster that helped turn it into one of Asia’s most valuable drugmakers. Now, with patent expirations looming in 2019, Chief Executive Officer Yoshihiko Hatanaka is setting off on a hunt for his next best seller.
Armed with about $3.6 billion in cash, the Japanese drugmaker is assessing various investment options.
comments powered by